Consensus Dr. Reddy's Laboratories Limited

Equities

500124

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:56:42 15/05/2026 pm IST			5-day change	1st Jan Change
1,336.95 ^INR	+2.62%		+3.38%	+5.18%

16/05	Dr. Reddy?S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada	CI
15/05	Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	MT

Evolution of the Average Target: Dr. Reddy's Laboratories Limited

Evolution of the Target Price: Dr. Reddy's Laboratories Limited

Changes in Analyst Recommendations: Dr. Reddy's Laboratories Limited

f0d96edf1bd62989708d629.9vwzj3xDCjkGo9GMsJinNXpe2XnQIbgJasuXDetZPKs.lY1huhIZc1Vw1KO6gvWTAi4rry6Dd_dBPJjNeLw1dvi4pXi3Six6c3PIlA~22a479c4f526c03d309ab97f835eb02d

Analysts' recommendations: Dr. Reddy's Laboratories Limited

23/01	YES Research Upgrades Dr. Reddy's Laboratories to Add from Reduce, Price Target is INR1,340	MT
23/01	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,600 From INR1,580, Keeps at Buy	MT
22/01	ICICI Securities Upgrades Dr. Reddy's Laboratories to Add from Hold, Price Target is INR1,300	MT
22/01	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,040 from INR1,100, Keeps at Underperform	MT
30/25/30	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy	MT
27/25/27	Choice Equity Upgrades Dr. Reddy's Laboratories to Add from Reduce; Price Target is INR1,380	MT
27/25/27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,650 From INR1,660, Keeps at Buy	MT
27/25/27	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,100, Keeps at Underperform	MT
13/25/13	BNP Paribas Exane Initiates Dr. Reddy's Laboratories at Neutral With $13.18 Price Target	MT
25/25/25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,660 From INR1,575, Keeps at Buy	MT
24/25/24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,100 From INR1,010, Keeps at Underperform	MT
12/25/12	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,010 from INR1,170, Keeps at Underperform	MT
27/25/27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,575 From INR1,500, Keeps at Buy	MT
24/25/24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform	MT
20/24/20	Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees	MT
06/24/06	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform	MT
29/24/29	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR5,600 From INR5,010, Keeps at Underperform	MT
08/24/08	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	MT
29/24/29	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	MT
30/23/30	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	MT
27/23/27	Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	MT
01/23/01	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	MT
30/23/30	Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	MT
25/22/25	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating	MT
12/22/12	Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DR. REDDY'S LABORATORIES LIMITED					-0.52%
	ELI LILLY AND COMPANY					+20.41%
	JOHNSON & JOHNSON					+11.58%
	ABBVIE INC.					+20.2%
	ROCHE HOLDING AG					+11.76%
	NOVARTIS AG					+4.77%
	ASTRAZENECA PLC					+22.12%
	MERCK & CO., INC.					+16.48%
	NOVO NORDISK A/S					+2.94%
	AMGEN INC.					+7.94%
	Average					+11.77%
	Weighted average by Cap.					+14.84%